Trial Profile
A multi-centre randomised, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of ART621 following multiple dose administration for 3 months in patients with rheumatoid arthritis concomitantly taking methotrexate.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Placulumab (Primary) ; Placulumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Arana Therapeutics
- 03 Feb 2010 New source identified and integrated (Clinical Trials Registry - India, CTRI2009-091-000569).
- 07 Jan 2010 Actual patient number (13) added as reported by ClinicalTrials.gov.
- 07 Jan 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.